ELEKTRA Study in Dravet and Lennox-Gastaut Syndromes
Inaccuracies With Valproic Acid Free Concentration Identified in Status Epilepticus
The calculation of fVPA based on this equation resulted in a misinterpretation in 40% of measurements with around 75% of them overestimating the actual measured fVPA.
Pavel Klein, MD: Determining Likelihood of Efficacy and AEs in Patient Populations
The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.
Praxis Medicines Wins Rare Disease and Orphan Drug Designations for DEEs
Including these agents for developmental and epileptic encephalopathies, the relatively young company has 5 programs under development to target rare neurological disorders.
TS Alliance E-Webinar Series
A look into the numerous education series upcoming in 2021 by the Tuberous Sclerosis Alliance
CYCLE-AD Trial: High-Intensity Exercise to Stave Off Alzheimer Disease
New NIH-funded study tests home-based intervention in high-risk group.
FDA Clears First Rapid Traumatic Brain Injury Blood Test
Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%, according to Abbott, the test’s developer.
Dietary Vitamin C and E Associated with Lower Risk of Parkinson Disease
Further associations with lowered risk of Parkinson were observed with BMI and coffee intake.
Richard B. Lipton, MD: Achieving Simultaneous Acute and Preventive Migraine Treatment
The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.
Causal Link Between Smoking and Subarachnoid Hemorrhage
People who were genetically predisposed to smoking behaviors were at a 63% greater risk for subarachnoid hemorrhage.
Anti-CD20 Monoclonal Antibodies for Treatment of RMS
Inconsistencies Identified Across EEG Neurology Education Tactics
The findings showed that 64% of EEG education programs did not utilize objective measures to assess EEG milestones.
The Role of Developing Agents in Acute Migraine Paradigm
CGRP Receptor Agonists: Safety and Efficacy
5-HT1F Agonist Toxicity Profile and Role in Paradigm
The Significance of 5-HT1F Agonist Approval
Recent Approvals for Acute Migraine
The Importance of Patient Communication
Therapy Assessment: Pain Relief & Onset Monitorization
Acute Migraine Treatment: Pain Freedom and Guidelines
Goals of and Recommended Approach for Acute Treatment
Acute Migraine Management: Overview and Unmet Needs
This Week on NeurologyLive — January 18, 2021
Here's what is coming soon to NeurologyLive.
Safety and Efficacy of CBD in Patients With TSC
NMOSD Early Age of Onset Predicts Severe Residual Vision Loss
Patients with an early age of onset (AO) were also more likely to receive less effective first-line oral therapy than those with later AOs.
William Rosenfeld, MD: Reducing Concomitant ASM Dosages for Focal Seizures
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.
Raymond Sanchez, MD: Phase 2 Trial Data of Tavapadon in Parkinson Disease
The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.
Biogen, Apple to Initiate Study to Develop Cognitive Health Digital Biomarkers
Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that’s expected to kick off later this year.
Helius Technologies Submits FDA Response in Pursuit of PoNS De Novo Classification
The FDA previously declined to approve de novo classification in April 2019.
NeurologyLive Friday 5 — January 15, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.
